Oncology

News

Roche's TIGIT ambitions take another blow

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste

News

Nykode vaccine shows its worth in cervical cancer trial

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.

News

Game used to track symptoms in children with cancer

A study has shown that a mobile game can be used to gather symptom data from children undergoing treatment for cancer, and potentially might also be used to provide personalised management

News

Manufacturing foul-up hits Novartis' radioligand business

Novartis has shut down production of its radioligand therapies – one of its key

News

AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer

The FDA has kicked off a priority review of AstraZeneca's checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for an immunotherapy for the group o

News

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Roche's TIGIT ambitions take another blow

Nykode vaccine shows its worth in cervical cancer trial

Game used to track symptoms in children with cancer

Manufacturing foul-up hits Novartis' radioligand business

AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

Oncology

Editor's Picks